Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

490
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
490
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

376
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
376
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

539
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
539

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A nationwide multi-centre survey of 12,500 cases of upper gastrointestinal bleeding: A report of Indian Society of Gastroenterology Task Force on acute upper gastrointestinal bleed.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

European Journal of Heart Failure International Expert Position Paper Utilisation, Optimisation, and Clinical Benefits of Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure with a Reduced Ejection Fraction.

European journal of heart failure·2026
Same author

Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker Combination Therapy With Reference to Telmisartan and Cilnidipine.

Cureus·2026
Same author

Retrospective Observational Electronic Medical Records-based Real World Study to Assess the Prevalence and Treatment of Dyslipidemia in Indian Patients.

The Journal of the Association of Physicians of India·2025
Same author

Expert Consensus on Lifestyle Modifications in Hypertension Management: An Indian Perspective.

The Journal of the Association of Physicians of India·2025
Same author

Beyond Amlodipine-The Case for S-amlodipine as the First Choice Calcium Channel Blocker: An Expert Opinion from India.

The Journal of the Association of Physicians of India·2025

Related Experiment Video

Updated: Jul 11, 2025

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.9K

Cardiovascular Compatibility of Proton Pump Inhibitors: Practice Recommendations.

Jamshed Dalal1, Anjan Lal Dutta2, Jagdish Hiremath3

  • 1Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. jamshed.dalal@relianceada.com.

Cardiology and Therapy
|November 10, 2023
PubMed
Summary

Proton pump inhibitors (PPIs) may have cardiovascular risks in coronary artery disease patients. Experts recommend PPIs with minimal drug interactions, like rabeprazole, especially for those on clopidogrel or multiple medications.

Keywords:
CYP450 enzymeCardiovascular riskClopidogrelPolypharmacyProton pump inhibitorsRabeprazole

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.0K

Related Experiment Videos

Last Updated: Jul 11, 2025

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.9K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.0K

Area of Science:

  • Cardiology
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Proton pump inhibitors (PPIs) are widely used for GERD and GI bleeding prevention.
  • Concerns exist regarding potential adverse cardiovascular effects of PPIs, particularly in patients with coronary artery disease (CAD).
  • Managing polypharmacy and drug-drug interactions (DDIs) is crucial in cardiovascular patient care.

Purpose of the Study:

  • To critically evaluate evidence on cardiovascular risks associated with PPIs in CAD patients.
  • To provide guidance on selecting appropriate PPIs considering cardiovascular polypharmacy.
  • To emphasize the need for PPIs with limited CYP450 inhibition to minimize DDIs.

Main Methods:

  • Review of available literature on PPIs and cardiovascular effects.
  • Proceedings from a consensus meeting of Indian cardiology and gastroenterology experts.
  • Evaluation of 14 consensus statements through multiple review rounds.

Main Results:

  • Consensus reached on the need for PPIs with minimal drug-drug interactions (DDIs).
  • Recommendation for PPIs with limited cytochrome P450 (CYP450) enzyme inhibition.
  • Rabeprazole identified as a suitable option due to optimal acid suppression and minimal DDI profile.

Conclusions:

  • PPI selection should prioritize minimal DDIs, especially in patients on clopidogrel or polypharmacy.
  • Clinicians should aim for consensus on prescribing PPIs with low CYP450 interaction potential.
  • Rabeprazole offers a favorable profile for co-prescription in cardiovascular patients requiring PPIs.